Ronald Reagan Ucla
- Type
- Teaching hospital
- Where
- Los Angeles, CA
- Medicare CCN
- 050262
- Received
- $36,247,085 in 2,002 records, 2023 ($3,149,164 general, $33,097,920 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2023 | General payment | 307 | $3,149,164 |
| 2023 | Research payment | 1,695 | $33,097,920 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 1,695 | $33,097,920 |
| Grant | 64 | $1,312,782 |
| Royalty or License | 35 | $800,252 |
| Space rental or facility fees (teaching hospital only) | 83 | $518,630 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 16 | $194,118 |
| Education | 72 | $115,222 |
| Long term medical supply or device loan | 4 | $89,099 |
| Gift | 6 | $85,046 |
| Debt forgiveness | 25 | $25,911 |
| Consulting Fee | 2 | $8,100 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2023-12-31 | Merck Sharp & Dohme LLC | $3,484,180 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | Randomized, Placebo-Controlled Trial to Evaluate the Safety of Letermovir PrevymisTM in Adults with Human Immunodeficien | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $672,351 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase II open-label, single arm pilot study to evaluate the safety and efficacy of pembrolizumab for high-grade vulvar | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $589,682 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $491,481 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase I surgical trial to evaluate early immunologic pharmacodynamic parameters for the PD-1 antibody pembrolizumab with | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $434,049 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A single-arm, open-label, phase II study of CHeckpoint inhibitors in men with prOgressive Metastatic castrate resistant | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $411,222 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multi-center, Double-Blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 plus Pem | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $396,027 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bel | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $355,810 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | A prospective digital quality improvement project to apply best clinical practices to patients at high risk of respirato | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $338,050 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase II open label, single arm study to evaluate the efficacy of pembrolizumab for leukoplakia | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $239,233 | Research payment | Cash or cash equivalent | Biological, CARDIOVASCULAR | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Ba | 2023 |
| 2023-12-31 | Siemens Medical Solutions USA, Inc. | $224,438 | Research payment | In-kind items and services | UCLA2020MRIPR926IPR928IPR932IPR938IPR941IPR963IPR990IPR996IPR1315Wu | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $217,992 | Research payment | Cash or cash equivalent | Biological, CARDIOVASCULAR | An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arteri | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $189,425 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $181,840 | Research payment | Cash or cash equivalent | Biological, CARDIOVASCULAR | A Phase 3, Randomized Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $162,388 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A phase I,II trial of intratumoral administration of CCL21-gene modified dendritic cell DC combined with pembrolizumab f | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $130,548 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Study of Pembrolizumab MK-3475 in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $110,278 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase II Study of Pembrolizumab Monotherapy in Recurrent Ovarian Cancer of the Immunoreactive Subtype determined by Na | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $102,787 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Thera | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $97,487 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab MK-3475 Versus N | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $91,525 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1,2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or P | 2023 |
| 2023-12-31 | AstraZeneca Pharmaceuticals LP | $81,179 | Research payment | In-kind items and services | TAGRISSO Drug, Oncology | A Phase III, Randomised, Controlled, Multi-centre Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $76,903 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-79 | 2023 |
| 2023-12-31 | AngioDynamics, Inc. | $60,000 | Long term medical supply or device loan | In-kind items and services | NanoKnife Device, Oncology Surgery | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $59,544 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1,Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab MK-34 | 2023 |
| 2023-12-31 | Aadi Bioscience, Inc. | $56,747 | Research payment | In-kind items and services | FYARRO Drug, Oncology | Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/_TSC2 | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $52,072 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $51,015 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1,2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or P | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $44,229 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1,2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or P | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $33,147 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1,2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or P | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $30,483 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab MK-3475 Versus N | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $28,472 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-r | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $27,378 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-79 | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $26,147 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bel | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $25,594 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $23,840 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK 7684A Vibostolimab with | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $23,372 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase Ib,II Trial of Pembrolizumab MK-3475 Combination Therapies in Metastatic Castration-Resistant Prostate Cancer mCRP | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $21,932 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Multi-center, Double-Blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 plus Pem | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $19,448 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel,Nab-Paclitaxel Chemotherapy with or without Pembro | 2023 |
| 2023-12-31 | Siemens Medical Solutions USA, Inc. | $18,458 | Research payment | In-kind items and services | UCLAMcNittGrayBodyClinicalPhysicsCT | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $18,331 | Research payment | In-kind items and services | VERQUVO Drug, CARDIOVASCULAR | A Phase 2,3 Randomized, Placebo-Controlled, Double-blind, Clinical Study to Evaluate the Efficacy, Safety, and Pharmacok | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $16,390 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib E7080,MK-7902 plus Pembrolizumab MK-3475 p | 2023 |
| 2023-12-31 | Siemens Medical Solutions USA, Inc. | $16,313 | Research payment | In-kind items and services | UCLA2021MRIPR899IPR991IPR992IPR1036Wu | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $13,831 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A PHASE III RANDOMIZED, PLACEBO-CONTROLLED STUDY OF PEMBROLIZUMAB MK-3475, NSC #776864 IN ADDITION TO PACLITAXEL AND CAR | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $13,754 | Research payment | In-kind items and services | Biological, CARDIOVASCULAR | A Phase 2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sotatercept M | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $13,726 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-r | 2023 |
| 2023-12-31 | Siemens Medical Solutions USA, Inc. | $13,500 | Research payment | In-kind items and services | UCLA2020MRIPR1315Wu | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $13,022 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Thera | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $12,680 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $12,406 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $10,861 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III Study of Pembrolizumab MK-3475 vs. Chemotherapy in Microsatellite Instability-High MSI-H or Mismatch Repair | 2023 |
| 2023-12-31 | Siemens Medical Solutions USA, Inc. | $10,688 | Research payment | In-kind items and services | UCSDLiuNeuroClinicalMR2021 | 2023 | |
| 2023-12-31 | Siemens Medical Solutions USA, Inc. | $9,450 | Research payment | In-kind items and services | UCLAWuMSKSequenceMR2021 | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $9,312 | Research payment | In-kind items and services | Biological, CARDIOVASCULAR | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Ba | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $8,977 | Research payment | In-kind items and services | DESCOVY Drug, INFECTIOUS DISEASE | A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of Oral Islatr | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $8,880 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $8,344 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $7,287 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine,Cisplatin versus Placebo Plus Gemcitabine,Cis | 2023 |
| 2023-12-31 | AstraZeneca Pharmaceuticals LP | $7,198 | Research payment | In-kind items and services | IMFINZI Biological, Oncology | A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Co | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $6,863 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma# A Randomized, Double-blind P | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $6,804 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | TACTI-002 Two ACTive Immunotherapeutics# A multicenter, open label, Phase II study in patients with previously untreated | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $6,179 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $6,175 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2023 |
| 2023-12-31 | Nidek Incorporated | $6,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | Diagnostic Device, Diagnostic | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $4,957 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $4,853 | Research payment | In-kind items and services | Biological, CARDIOVASCULAR | A Phase 3, Randomized Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $4,721 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- MK-3475, SCH 900475 Based Combination Therapy f | 2023 |
| 2023-12-31 | Siemens Medical Solutions USA, Inc. | $4,125 | Research payment | In-kind items and services | UCLA2020MRIPR928Ellingson | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $4,085 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized Double-Blind, Phase III Study of PlatinumPemtrexed Chemotherapy with or without Pembrolizumab MK-3475 in Fi | 2023 |
| 2023-12-31 | Siemens Medical Solutions USA, Inc. | $3,750 | Research payment | In-kind items and services | UCLA2020MRIPR1111Nguyen | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $3,586 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $3,552 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A PHASE III RANDOMIZED, PLACEBO-CONTROLLED STUDY OF PEMBROLIZUMAB MK-3475, NSC #776864 IN ADDITION TO PACLITAXEL AND CAR | 2023 |
| 2023-12-31 | KARL STORZ Endoscopy-America | $3,530 | Education | In-kind items and services | IMAGE1 S CONNECT Device, VIDEOIMAGING | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $3,326 | Research payment | In-kind items and services | VERQUVO Drug, CARDIOVASCULAR | A Phase 2,3 Randomized, Placebo-Controlled, Double-blind, Clinical Study to Evaluate the Efficacy, Safety, and Pharmacok | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $2,866 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemothera | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $2,768 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-r | 2023 |
| 2023-12-31 | Siemens Medical Solutions USA, Inc. | $2,625 | Research payment | In-kind items and services | UCLA2022MRIPR1084Wu | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $2,468 | Research payment | In-kind items and services | Biological, CARDIOVASCULAR | An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arteri | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $1,726 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment | 2023 |
| 2023-12-31 | ABBVIE INC. | $1,575 | Research payment | In-kind items and services | A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxol | 2023 | |
| 2023-12-31 | AstraZeneca Pharmaceuticals LP | $1,563 | Research payment | In-kind items and services | LYNPARZA Drug, Oncology | \";A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in P | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $1,488 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination wit | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $1,485 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Sche | 2023 |
| 2023-12-31 | AstraZeneca Pharmaceuticals LP | $1,131 | Research payment | In-kind items and services | IMFINZI Biological, Oncology | A Phase III Randomized Open-Label Controlled Multi-Center Global Study of First-Line Durvalumab in Combination with Stan | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $1,092 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus | 2023 |
| 2023-12-31 | Siemens Medical Solutions USA, Inc. | $1,040 | Research payment | In-kind items and services | UCLA2023MRIPR814859Kumar | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $928 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Sche | 2023 |
| 2023-12-31 | AstraZeneca Pharmaceuticals LP | $870 | Research payment | In-kind items and services | TAGRISSO Drug, Oncology | To assess the efficacy and safety of AZD9291 versus Placebo in patients with Epidermal Growth Factor Receptor Mutation P | 2023 |
| 2023-12-31 | KARL STORZ Endoscopy-America | $766 | Education | In-kind items and services | IMAGE1 S CONNECT Device, VIDEOIMAGING | 2023 | |
| 2023-12-31 | Siemens Medical Solutions USA, Inc. | $652 | Research payment | In-kind items and services | UCSD2023MRIPR794992Liu | 2023 | |
| 2023-12-31 | Philips North America LLC | $620 | Long term medical supply or device loan | In-kind items and services | (2013) Sleep Therapy Modems Device, Medical Device | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $559 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase I,II clinical trial to study the safety and tolerability of MK-3475 Pegylated Interferon alfa-2b PEG-IFN and MK | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $559 | Research payment | In-kind items and services | JANUVIA Drug, ENDOCRINOLOGY | TECOS# A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitaglip | 2023 |
| 2023-12-31 | AstraZeneca Pharmaceuticals LP | $484 | Research payment | In-kind items and services | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF DATO-DXD VERSUS INVESTIGATORS CHOICE OF CHEMOTHERAPY IN PARTICIPANTS WITH INO | 2023 | |
| 2023-12-31 | AstraZeneca Pharmaceuticals LP | $445 | Research payment | In-kind items and services | A Biomarker-Directed Phase 2 Platform Study in Patients with Advanced Non-Small Cell Lung Cancer whose Disease has Progr | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $379 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently | 2023 |
| 2023-12-31 | AstraZeneca Pharmaceuticals LP | $304 | Research payment | In-kind items and services | A Modular Phase I Open-Label Multicentre Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Anti-t | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $264 | Research payment | In-kind items and services | Biological, CARDIOVASCULAR | A Phase 2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sotatercept M | 2023 |
| 2023-12-31 | Acerta Pharma LLC | $243 | Research payment | In-kind items and services | CALQUENCE Drug, Oncology | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreat | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $223 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination wit | 2023 |
| 2023-12-31 | KARL STORZ Endoscopy-America | $126 | Education | In-kind items and services | n.a. Device, OTHER MISC | 2023 | |
| 2023-12-31 | KARL STORZ Endoscopy-America | $120 | Education | In-kind items and services | n.a. Device, OTHER MISC | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $112 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot | 2023 |
| 2023-12-31 | Philips North America LLC | $106 | Long term medical supply or device loan | In-kind items and services | (2013) Sleep Therapy Modems Device, Medical Device | 2023 | |
| 2023-12-31 | KARL STORZ Endoscopy-America | $60 | Education | In-kind items and services | n.a. Device, OTHER MISC | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $6 | Research payment | Cash or cash equivalent | JANUVIA Drug, ENDOCRINOLOGY | TECOS# A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitaglip | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $5 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III Randomized Clinical Trial of Pembrolizumab MK-3475 versus Paclitaxel, Docetaxel or Vinflunine in Subjects wi | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $1 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase I Study of Single Agent MK-3475 in Patients with Progressive Locally Advanced or Metastatic Carcinomas and Melanom | 2023 |
| 2023-12-28 | Mallinckrodt Hospital Products Inc. | $16,477 | Debt forgiveness | Cash or cash equivalent | INOMAX Drug, CRITICAL CARE | 2023 | |
| 2023-12-28 | Olympus America Inc. | $22 | Debt forgiveness | In-kind items and services | 2023 | ||
| 2023-12-27 | InSightec,LTD | $49,615 | Research payment | Cash or cash equivalent | Exablate Device, NEUROLOGY | BT015 | 2023 |
| 2023-12-27 | Servier BioInnovation | $32,188 | Research payment | In-kind items and services | Tibsovo Drug, Oncology | STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA | 2023 |
| 2023-12-27 | Servier BioInnovation | $32,188 | Research payment | In-kind items and services | Tibsovo Drug, Oncology | STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA | 2023 |
| 2023-12-27 | Servier BioInnovation | $32,188 | Research payment | In-kind items and services | Tibsovo Drug, Oncology | STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA | 2023 |
| 2023-12-27 | Servier BioInnovation | $32,188 | Research payment | In-kind items and services | Tibsovo Drug, Oncology | STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA | 2023 |
| 2023-12-27 | United Therapeutics Corporation | $15,961 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2023 |
| 2023-12-27 | United Therapeutics Corporation | $15,609 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2023 |
| 2023-12-26 | MACROGENICS, INC. | $1,581 | Research payment | Cash or cash equivalent | A PHASE 1 1B DOSE ESCALATION AND COHORT EXPANSION STUDY OF MGC018 IN COMBINATION WITH CHECKPOINT INHIBITOR IN PARTICIPAN | 2023 | |
| 2023-12-26 | MACROGENICS, INC. | $1,110 | Research payment | Cash or cash equivalent | A PHASE 1 1B DOSE ESCALATION AND COHORT EXPANSION STUDY OF MGC018 IN COMBINATION WITH CHECKPOINT INHIBITOR IN PARTICIPAN | 2023 | |
| 2023-12-26 | MACROGENICS, INC. | $672 | Research payment | Cash or cash equivalent | A PHASE 1 1B DOSE ESCALATION AND COHORT EXPANSION STUDY OF MGC018 IN COMBINATION WITH CHECKPOINT INHIBITOR IN PARTICIPAN | 2023 | |
| 2023-12-25 | Janssen Research & Development, LLC | $7,321 | Research payment | Cash or cash equivalent | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ6 | 2023 | |
| 2023-12-22 | Hoffmann-La Roche Limited | $16,884 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | Morpheus Breast | 2023 |
| 2023-12-22 | Hoffmann-La Roche Limited | $10,668 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | Morpheus Breast | 2023 |
| 2023-12-22 | JAZZ PHARMACEUTICALS INC. | $2,465 | Research payment | Cash or cash equivalent | EPIDIOLEX Drug, NEUROLOGY | AN EXPLORATORY, PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO INVESTIGATE THE SAFETY AND EFFICACY OF CA | 2023 |
| 2023-12-22 | JAZZ PHARMACEUTICALS INC. | $586 | Research payment | Cash or cash equivalent | EPIDIOLEX Drug, NEUROLOGY | AN EXPLORATORY, PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO INVESTIGATE THE SAFETY AND EFFICACY OF CA | 2023 |
| 2023-12-21 | Nucletron Operations B.V. | $23,750 | Royalty or License | Cash or cash equivalent | FLEXITRON HDR Device, Brachy Solutions | 2023 | |
| 2023-12-21 | Novartis Pharmaceuticals Corporation | $10,962 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine With or Without MBG453 for th | 2023 | |
| 2023-12-21 | Sarepta Therapeutics, Inc. | $8,562 | Research payment | Cash or cash equivalent | SRP-9001-102 | 2023 | |
| 2023-12-21 | Sarepta Therapeutics, Inc. | $7,092 | Royalty or License | Cash or cash equivalent | 2023 | ||
| 2023-12-21 | Abbott Laboratories | $5,000 | Education | Cash or cash equivalent | 2023 | ||
| 2023-12-21 | Immunocore Limited | $2,415 | Research payment | Cash or cash equivalent | KIMMTRAK Drug, Oncology | A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigators | 2023 |
| 2023-12-21 | Sarepta Therapeutics, Inc. | $1,260 | Research payment | Cash or cash equivalent | SRP-9001-102 | 2023 | |
| 2023-12-21 | Medical Device Business Services, Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | CARTO 3 Device, Cardiology | 2023 | |
| 2023-12-21 | Advanced Bionics, LLC | $977 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | HIRES ULTRA CI HIFOCUS MS ELECTRODE Device, OTOLARYNGOLOGY | 2023 | |
| 2023-12-20 | Merck Sharp & Dohme LLC | $88,719 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Thera | 2023 |
| 2023-12-20 | Genentech, Inc. | $65,453 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | PHASE Ib II STUDY EVALUATING THE EFFICACY AND SAFETY OF TREATMENT COMBINATIONS IN HCC MORPHEUS HCC | 2023 |
| 2023-12-20 | Genentech, Inc. | $24,322 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | PHASE Ib II STUDY EVALUATING THE EFFICACY AND SAFETY OF TREATMENT COMBINATIONS IN HCC MORPHEUS HCC | 2023 |
| 2023-12-20 | Genentech, Inc. | $18,081 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | PHASE Ib II STUDY EVALUATING THE EFFICACY AND SAFETY OF TREATMENT COMBINATIONS IN HCC MORPHEUS HCC | 2023 |
| 2023-12-20 | Genentech, Inc. | $2,205 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | DLBCL Salvage SD PD or Consolidation PR post Induction Therapy 1L DLBCL in Elderly Frail | 2023 |
| 2023-12-20 | Immunocore Limited | $650 | Research payment | Cash or cash equivalent | KIMMTRAK Drug, Oncology | A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination with Durvalumab (MEDI | 2023 |
| 2023-12-20 | Immunocore Limited | $650 | Research payment | Cash or cash equivalent | KIMMTRAK Drug, Oncology | A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination with Durvalumab (MEDI | 2023 |
| 2023-12-20 | Immunocore Limited | $650 | Research payment | Cash or cash equivalent | KIMMTRAK Drug, Oncology | A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination with Durvalumab (MEDI | 2023 |
| 2023-12-20 | Immunocore Limited | $650 | Research payment | Cash or cash equivalent | KIMMTRAK Drug, Oncology | A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination with Durvalumab (MEDI | 2023 |
| 2023-12-20 | Immunocore Limited | $650 | Research payment | Cash or cash equivalent | KIMMTRAK Drug, Oncology | A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination with Durvalumab (MEDI | 2023 |
| 2023-12-20 | Immunocore Limited | $260 | Research payment | Cash or cash equivalent | KIMMTRAK Drug, Oncology | A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination with Durvalumab (MEDI | 2023 |
| 2023-12-19 | Mylan Specialty L.P. | $31,338 | Research payment | Cash or cash equivalent | YUPELRI Drug, Anticholinergics, Inhaled | Revefenacin in Acute Respiratory Insufficiency in COPD (RARICO) | 2023 |
| 2023-12-19 | Teva Pharmaceuticals USA, Inc. | $9,430 | Research payment | Cash or cash equivalent | AUSTEDO Drug, Central Nervous System | TV50717-CNS-40189 | 2023 |
| 2023-12-18 | Merck Sharp & Dohme LLC | $552,132 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | First-in-Human, Phase 1,1b, Open-label, Multicenter Study of Bifunctional EGFR,TGF Fusion Protein BCA101 Monotherapy an | 2023 |
| 2023-12-18 | Merck Sharp & Dohme LLC | $99,301 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab in Metastatic Colorectal Cancer | 2023 |
| 2023-12-18 | Merck Sharp & Dohme LLC | $86,788 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy | 2023 |
| 2023-12-18 | Immedica Pharma US, Inc. | $23,137 | Research payment | Cash or cash equivalent | A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intravenous Ganaxolone in St | 2023 | |
| 2023-12-18 | Eli Lilly and Company | $710 | Research payment | In-kind items and services | SUNRAY-01 A GLOBAL PIVOTAL STUDY IN PARTICIPANTS WITH KRAS G12C-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUN | 2023 | |
| 2023-12-18 | Janssen Research & Development, LLC | $504 | Research payment | Cash or cash equivalent | A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participan | 2023 | |
| 2023-12-15 | Gamida Cell Inc. | $40,757 | Research payment | Cash or cash equivalent | OMISIRGE Biological, ONCOLOGY | EXPANDED ACCESS OF OMIDUBICEL, FOR ALLOGENEIC TRANSPLANTATION IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES | 2023 |
| 2023-12-15 | Genentech, Inc. | $6,617 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | DLBCL Salvage SD PD or Consolidation PR post Induction Therapy 1L DLBCL in Elderly Frail | 2023 |
| 2023-12-14 | Actelion Pharmaceuticals US, Inc. | $344,650 | Grant | Cash or cash equivalent | 2023 | ||
| 2023-12-14 | Horizon Therapeutics plc | $22,471 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, REPEAT-DOSE, MULTICENTER TRIAL TO EVALUATE THE EFFICACY, SAFETY, TOLERAB | 2023 | |
| 2023-12-14 | Janssen Biotech, Inc. | $5,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ERLEADA Drug, Oncology | 2023 | |
| 2023-12-14 | ABBVIE INC. | $2,036 | Research payment | Cash or cash equivalent | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving | 2023 | |
| 2023-12-14 | ABBVIE INC. | $1,781 | Research payment | Cash or cash equivalent | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving | 2023 | |
| 2023-12-14 | ABBVIE INC. | $1,781 | Research payment | Cash or cash equivalent | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving | 2023 | |
| 2023-12-14 | Ipsen Pharma SAS | $1,375 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2023 |
| 2023-12-13 | Merck Sharp & Dohme LLC | $534,686 | Research payment | Cash or cash equivalent | WELIREG Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bel | 2023 |
| 2023-12-13 | Astellas Pharma Global Development | $25,200 | Research payment | Cash or cash equivalent | Xospata Drug, Oncology | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Ve | 2023 |
| 2023-12-13 | TAIHO ONCOLOGY, INC. | $19,536 | Research payment | Cash or cash equivalent | LYTGOBI Drug, Oncology | A Phase 1b/2 Open-label, Nonrandomized Study of FGFR Inhibitor Futibatinib in Combination With MEK-inhibitor Binimetinib | 2023 |
| 2023-12-13 | TAIHO ONCOLOGY, INC. | $13,845 | Research payment | Cash or cash equivalent | LYTGOBI Drug, Oncology | A Phase 1b/2 Open-label, Nonrandomized Study of FGFR Inhibitor Futibatinib in Combination With MEK-inhibitor Binimetinib | 2023 |
| 2023-12-13 | TAIHO ONCOLOGY, INC. | $9,140 | Research payment | Cash or cash equivalent | LYTGOBI Drug, Oncology | A Phase 1b/2 Open-label, Nonrandomized Study of FGFR Inhibitor Futibatinib in Combination With MEK-inhibitor Binimetinib | 2023 |
| 2023-12-13 | Astellas Pharma Global Development | $6,300 | Research payment | Cash or cash equivalent | Xospata Drug, Oncology | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Ve | 2023 |
| 2023-12-13 | Astellas Pharma Global Development | $4,038 | Research payment | Cash or cash equivalent | Xospata Drug, Oncology | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Ve | 2023 |
| 2023-12-13 | Astellas Pharma Global Development | $3,528 | Research payment | Cash or cash equivalent | Xospata Drug, Oncology | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Ve | 2023 |
| 2023-12-13 | Astellas Pharma Global Development | $3,120 | Research payment | Cash or cash equivalent | Xospata Drug, Oncology | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Ve | 2023 |
| 2023-12-13 | Regeneron Pharmaceuticals, Inc. | $3,049 | Research payment | Cash or cash equivalent | A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH AN INTRAVENOUS PD-1-BLOCKING ANTIBO | 2023 | |
| 2023-12-13 | Regeneron Pharmaceuticals, Inc. | $2,957 | Research payment | Cash or cash equivalent | A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH AN INTRAVENOUS PD-1-BLOCKING ANTIBO | 2023 | |
| 2023-12-13 | Regeneron Pharmaceuticals, Inc. | $2,831 | Research payment | Cash or cash equivalent | A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH AN INTRAVENOUS PD-1-BLOCKING ANTIBO | 2023 | |
| 2023-12-13 | Astellas Pharma Global Development | $2,500 | Research payment | Cash or cash equivalent | Xospata Drug, Oncology | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Ve | 2023 |
| 2023-12-13 | TAIHO ONCOLOGY, INC. | $2,320 | Research payment | Cash or cash equivalent | LYTGOBI Drug, Oncology | A Phase 1b/2 Open-label, Nonrandomized Study of FGFR Inhibitor Futibatinib in Combination With MEK-inhibitor Binimetinib | 2023 |
| 2023-12-13 | Astellas Pharma Global Development | $1,890 | Research payment | Cash or cash equivalent | Xospata Drug, Oncology | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Ve | 2023 |
| 2023-12-13 | Regeneron Pharmaceuticals, Inc. | $1,639 | Research payment | Cash or cash equivalent | A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH AN INTRAVENOUS PD-1-BLOCKING ANTIBO | 2023 | |
| 2023-12-13 | Astellas Pharma Global Development | $1,594 | Research payment | Cash or cash equivalent | Xospata Drug, Oncology | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Ve | 2023 |
| 2023-12-13 | Astellas Pharma Global Development | $945 | Research payment | Cash or cash equivalent | Xospata Drug, Oncology | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Ve | 2023 |
| 2023-12-13 | Pharmacyclics LLC, an AbbVie Company | $459 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | 2023 |
| 2023-12-13 | Pharmacyclics LLC, an AbbVie Company | $367 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | 2023 |
| 2023-12-13 | TAIHO ONCOLOGY, INC. | $212 | Research payment | Cash or cash equivalent | LYTGOBI Drug, Oncology | A Phase 1b/2 Open-label, Nonrandomized Study of FGFR Inhibitor Futibatinib in Combination With MEK-inhibitor Binimetinib | 2023 |
| 2023-12-13 | Penumbra, Inc. | $120 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE-PE | 2023 |
| 2023-12-12 | Regeneron Pharmaceuticals, Inc. | $30,650 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2023 | ||
| 2023-12-12 | Siemens Medical Solutions USA, Inc. | $15,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-12-12 | United Therapeutics Corporation | $9,219 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2023 |
| 2023-12-12 | United Therapeutics Corporation | $9,042 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2023 |
| 2023-12-11 | SANOFI US SERVICES INC. | $9,132 | Research payment | Cash or cash equivalent | SARCLISA Biological, Oncology | A Phase 3 Randomized, Open Label, Multicenter Study of Isatuximab (SAR650984) in Combination With Lenalidomide and Dexam | 2023 |
| 2023-12-11 | Ipsen Pharma SAS | $2,998 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2023 |
| 2023-12-11 | Siemens Medical Solutions USA, Inc. | $443 | Research payment | In-kind items and services | UCLA2019MRIPR1066Lenartowicz | 2023 | |
| 2023-12-08 | W. L. Gore & Associates, Inc. | $15,730 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | GORE CARDIOFORM Septal Occluder Migraine Clinical Study: A Study to evaluate the safety and efficacy of transcatheter cl | 2023 |
| 2023-12-07 | Sarepta Therapeutics, Inc. | $26,588 | Research payment | Cash or cash equivalent | SRP-9001-102 | 2023 | |
| 2023-12-07 | Merck Sharp & Dohme LLC | $2,031 | Research payment | In-kind items and services | Biological, CARDIOVASCULAR | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Ba | 2023 |
| 2023-12-07 | Sarepta Therapeutics, Inc. | $1,663 | Research payment | Cash or cash equivalent | SRP-9001-102 | 2023 | |
| 2023-12-07 | Sarepta Therapeutics, Inc. | $585 | Research payment | Cash or cash equivalent | SRP-9001-102 | 2023 | |
| 2023-12-07 | Regeneron Pharmaceuticals, Inc. | $246 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2023 | ||
| 2023-12-06 | Aurinia Pharma U.S., Inc. | $24,767 | Research payment | Cash or cash equivalent | LUPKYNIS Drug, LUPUS NEPHRITIS | LUPKYNIS Registry Study | 2023 |
| 2023-12-06 | MACROGENICS, INC. | $6,696 | Research payment | Cash or cash equivalent | A STUDY OF TWO DOSE LEVELS OF VOBRAMITAMAB DUOCARMAZINE IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CA | 2023 | |
| 2023-12-05 | PTC Therapeutics, Inc. | $27,690 | Research payment | Cash or cash equivalent | A PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF UNESBULIN IN UNRESECTABLE OR METASTATIC, RELAPSED OR REFRACTORY | 2023 | |
| 2023-12-05 | PTC Therapeutics, Inc. | $9,450 | Research payment | Cash or cash equivalent | AN OPEN-LABEL, SAFETY STUDY FOR ATALUREN (PTC124) PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY | 2023 |
The latest 200 records of 2,002.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Los Angeles, CA, county Los Angeles County, CA, state California; placed by its city name.
| Measure | Place (city or town) Los Angeles, CA | County Los Angeles County, CA | State California |
|---|---|---|---|
| Population B01003 | 3,857,263 | 9,808,667 | 39,287,377 |
| Population, 2020 census P1 | 3,898,747 | 10,014,009 | 39,538,223 |
| Median age B01002 | 37.2 | 38.2 | 37.9 |
| Under 18 B01001 | 19.2% | 20.6% | 22.0% |
| 65 and over B01001 | 14.2% | 15.2% | 15.7% |
| Households B11001 | 1,439,097 | 3,416,449 | 13,548,091 |
| Foreign born B05002 | 35.7% | 33.4% | 27.0% |
| Median household income B19013 | $81,939 | $90,112 | $99,122 |
| Median family income B19113 | $94,546 | $101,573 | $113,346 |
| Per capita income B19301 | $47,685 | $45,792 | $49,513 |
| Poverty rate B17001 | 16.5% | 13.7% | 12.0% |
| Unemployment rate B23025 | 8.2% | 7.3% | 6.6% |
| Civilian labor force B23025 | 2,128,918 | 5,200,656 | 20,068,466 |
| Mean commute (minutes) B08013 | 30.7 | 30.4 | 28.7 |
| Bachelor's degree or higher B15003 | 38.5% | 36.0% | 37.1% |
| Housing units B25001 | 1,554,332 | 3,650,466 | 14,644,735 |
| Owner-occupied B25003 | 36.0% | 45.9% | 55.9% |
| Renters B25003 | 64.0% | 54.1% | 44.1% |
| Median home value B25077 | $921,200 | $834,200 | $734,700 |
| Median gross rent B25064 | $1,933 | $1,954 | $2,036 |
| White, not Hispanic B03002 | 28.1% | 24.7% | 33.8% |
| Black B03002 | 8.1% | 7.4% | 5.2% |
| Hispanic or Latino B03002 | 47.2% | 48.4% | 40.2% |
| Asian B03002 | 11.9% | 14.9% | 15.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Los Angeles, CA.
Comments